The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).
 
Eric Jeffrey Sherman
Consulting or Advisory Role - Bristol-Myers Squibb; Cota Healthcare; Eisai; Goldilocks; Loxo; Novartis
Research Funding - Eisai; Plexxikon; Roche/Genentech
 
C. Jillian Tsai
No Relationships to Disclose
 
Wanqing Iris Zhi
No Relationships to Disclose
 
James Vincent Fetten
No Relationships to Disclose
 
Vanessa Wu
No Relationships to Disclose
 
Alan Loh Ho
Consulting or Advisory Role - AstraZeneca; Ayala Pharmaceuticals; Bristol-Myers Squibb; Eisai; Genzyme; Merck; Novartis; Regeneron; Sanofi; Sun Pharma; TRM Oncology
Speakers' Bureau - Medscape; Novartis; Omniprex America
Research Funding - Allos Therapeutics; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; Ayala Pharmaceuticals; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech/Roche; Kolltan Pharmaceuticals; Kura Oncology; Lilly; Merck; Novartis; Novartis; Pfizer
Travel, Accommodations, Expenses - Ayala Pharmaceuticals; Ignyta; Janssen Oncology; Kura Oncology; Kura Oncology; Kura Oncology; Merck
 
Nadeem Riaz
Honoraria - PeerView
Speakers' Bureau - Illumina
Research Funding - Bristol-Myers Squibb; Pfizer
Travel, Accommodations, Expenses - Varian Medical Systems
 
David G. Pfister
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb; Celgene
Research Funding - AstraZeneca; Bayer (Inst); Boehringer Ingelheim; Eisai (Inst); Exelixis; Genentech/Roche (Inst); Lilly (Inst); MedImmune; Merck; Novartis; Regeneron
 
Nancy Y. Lee
Stock and Other Ownership Interests - AstraZeneca (I); AstraZeneca (I)
Consulting or Advisory Role - Merck; Merck Serono; pfizer; Sanofi
Research Funding - AstraZeneca